Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-03-20Clinical Trial Update: Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women [Phase 4]
Phase 4 study assessing the effectiveness and safety of solifenacin succinate alone and with estrogen for overactive bladder in postmenopaus…
-
CLINICAL_TRIALS trial_result · 2014-03-19Clinical Trial Update: Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence [Phase 2]
Phase 2 trial evaluating the safety and efficacy of AGN-214868 in adults with idiopathic overactive bladder and urinary incontinence complet…
-
FDA approval · 2014-03-13FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for MYRBETRIQ (mirabegron) filed by Astellas Pharma US, Inc., indicating an approved modification to…
-
CLINICAL_TRIALS trial_result · 2014-03-12Clinical Trial Update: A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. [Phase 2]
A Phase 2 trial update comparing Tarafenacin at 0.2 mg and 0.4 mg with placebo in patients with Overactive Bladder to evaluate efficacy and …
-
CLINICAL_TRIALS trial_result · 2014-02-05Clinical Trial Update: Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate [Phase 4]
Phase 4 trial comparing Percutaneous Tibial Nerve Stimulation (PTNS) alone versus PTNS with fesoterodine fumarate for Overactive Bladder was…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-01-24Clinical Trial Update: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder [Phase 3]
A Phase 3 safety and efficacy trial of botulinum toxin type A for neurogenic overactive bladder was terminated, with results posted in Janua…
-
CLINICAL_TRIALS trial_result · 2013-12-31Clinical Trial Update: Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
A clinical trial update assessing propiverine for overactive bladder syndrome reports on its efficacy, tolerability, and impact on quality o…
-
CLINICAL_TRIALS trial_result · 2013-12-24Clinical Trial Update: A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine [Phase 4]
Phase 4 trial comparing 8 mg to 4 mg fesoterodine for overactive bladder has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2013-12-19Clinical Trial Update: Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)
Astellas Pharma Europe has completed a clinical trial evaluating treatment for storage symptoms in men with lower urinary tract symptoms (ov…
-
CLINICAL_TRIALS research · 2013-12-12Clinical Trial Update: Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity [Phase 4]
Phase 4 clinical trial update evaluating botulinum toxin for idiopathic detrusor overactivity (overactive bladder).
-
CLINICAL_TRIALS trial_result · 2013-11-19Clinical Trial Update: An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome [Phase 3]
Phase 3 clinical trial update reports results for an implantable microstimulator intended to treat urinary urgency-frequency syndrome (overa…
-
CLINICAL_TRIALS trial_result · 2013-10-31Clinical Trial Update: Studies of Psychiatric Predisposing Factors, Treatment-related Cardiovascular Effects, and Prognostic Factors Associated With Antimuscarinic Drug (Tolterodine) for Female Overactive Bladder Syndrome [NA]
This entry notes a completed clinical trial investigating psychiatric predisposition factors, cardiovascular effects, and prognostic factors…
-
FDA approval · 2013-10-09FDA Approved: VESICARE — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for Vesicare (solifenacin succinate) from Astellas Pharma US, Inc. The approval updates the drug's l…
-
CLINICAL_TRIALS trial_result · 2013-09-26Clinical Trial Update: Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily [Phase 4]
Phase 4 clinical trial evaluating the efficacy of Sanctura XR (trospium chloride) for reducing overactive bladder symptoms in women refracto…
-
CLINICAL_TRIALS withdrawal · 2013-09-26Clinical Trial Update: Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
The clinical trial evaluating the effects of antimuscarinic drugs on overactive bladder symptoms following ureteral stent insertion has been…
-
CLINICAL_TRIALS trial_result · 2013-09-24Clinical Trial Update: Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of tolterodine ER in subjects with overactive bladder; study terminated with results…
-
CLINICAL_TRIALS trial_result · 2013-09-16Clinical Trial Update: An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants [Phase 4]
A Phase 4 efficacy and safety study of oxybutynin chloride OROS in Korean adults with overactive bladder completed, with results posted in 2…
-
FDA approval · 2013-08-30FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for oxybutynin chloride submitted by Chartwell RX, LLC.
-
FDA approval · 2013-08-29FDA Approved: TROSPIUM CHLORIDE — Supplemental Application (Padagis US LLC)
The FDA approved Padagis US LLC's supplemental application for trospium chloride, a generic drug used to treat overactive bladder.
-
FDA approval · 2013-08-20FDA Approved: OXYTROL FOR WOMEN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for OXYTROL FOR WOMEN (oxybutynin) from Allergan, Inc., updating labeling related to the product.
-
FDA approval · 2013-08-16FDA Approved: OXYTROL FOR WOMEN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for Oxytrol for Women (oxybutynin), a transdermal patch for overactive bladder in adult women.
-
FDA approval · 2013-07-31FDA Approved: OXYBUTYNIN CHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for oxybutynin chloride from Upsher-Smith Laboratories, LLC.
-
FDA approval · 2013-07-31FDA Approved: TROSPIUM CHLORIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves a supplemental application for trospium chloride (Glenmark Pharmaceuticals Inc., USA).
-
CLINICAL_TRIALS trial_result · 2013-07-31Clinical Trial Update: Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity [Phase 4]
This Phase 4 trial of extended-release oxybutynin for neurogenic detrusor overactivity was terminated. Results were posted in July 2013.
-
FDA approval · 2013-07-19FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for MYRBETRIQ (mirabegron) submitted by Astellas Pharma US, Inc.